Selective Beta-blockers
Selective Beta-blockers - Related Videos
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
02:08
Assessing Muscle Contraction with Neuromuscular Blocker Treatment
0 Views •
2025
This video demonstrates assessing the muscle using cultured motor neurons, Schwann cells, and myotubes, followed by treatment with a neuromuscular blocker to inhibit contraction. Color-coded time-motion graphics show a color-coded time-motion graphic. Red indicates the fastest movement, and blue indicates the slowest.
09:50
In situ Quantification of Pancreatic Beta-cell Mass in Mice
0 Views •
Cited by 6 •
2010
The following protocol outlines the process of pancreatic dissection for virtual slice imaging, and the subsequent quantification of all GFP-tagged beta-cells in the entire pancreas.
03:16
Intravenous Delivery of Receptor Blockers to Reduce Brain Edema in a Mouse Model
0 Views •
2025
Source: Zeynalov, E. et. al., Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J. Vis. Exp. (2016)This video demonstrates the intravenous delivery of an arginine-vasopressin (AVP) receptor antagonist in a mouse model. Transient middle cerebral artery occlusion induces brain edema. An AVP receptor antagonist is administered through a catheter in the left jugular vein, alleviating edema.
01:19
Depolarizing Blockers: Pharmocokinetics
0 Views •
2023
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
FAQs
Beta1 selectivity reflects a preference for beta1 receptors rather than complete exclusivity. At higher concentrations, the distinction between beta1 and beta2 blockade may diminish, increasing the possibility of beta2-related effects. This pharmacologic limitation matters when interpreting the relative safety advantages of agents such as metoprolol, atenolol, and bisoprolol across different treatment conditions.
Blocking beta1 receptors reduces the heart’s response to sympathetic stimulation by lowering heart rate and myocardial contractility. It also decreases renin release, linking receptor blockade to an additional effect on a system involved in cardiovascular regulation. Together, these actions explain why selective beta-blockers can influence several cardiovascular conditions rather than producing only a slowing of cardiac activity.
Selective beta-blockers preferentially inhibit beta1 receptors and therefore cause less beta2-receptor blockade than nonselective agents. This difference can reduce effects associated with beta2 inhibition in the bronchi and vasculature, although selectivity is incomplete and may decline at higher concentrations. The comparison is therefore one of relative receptor preference, not an absolute separation of effects.
Relative beta2-receptor sparing may lessen bronchial and vascular effects compared with broader beta-receptor blockade. That property can be relevant when pharmacologists compare agents for patients in whom respiratory effects are a concern. It does not eliminate risk, however, because susceptible patients may still require respiratory caution even when a beta1-preferring drug is selected.
Clinical uses include hypertension, angina, cardiac arrhythmias, and selected cases of heart failure. The same underlying beta1-mediated actions can produce different therapeutic value depending on the condition, such as reducing cardiac stimulation or limiting sympathetic effects on the heart. Selection for heart failure is described as selective rather than universal, so the clinical context remains important.
Metoprolol, atenolol, and bisoprolol are examples of selective beta-blocking agents used in cardiovascular pharmacology. They illustrate the drug class rather than establishing that every agent has identical clinical behavior. Their relevance comes from the shared pharmacologic aim of reducing beta1-mediated sympathetic effects while retaining relative, though not complete, beta2-receptor sparing.
Respiratory caution remains important because beta1 preference does not prevent all beta2-receptor blockade. The potential for beta2-related bronchial effects becomes especially relevant in susceptible patients and may also increase as drug concentrations rise. Pharmacologic assessment should therefore consider both the intended cardiac effects and the limits of receptor selectivity rather than assuming complete respiratory protection.
The principal outcomes are reduced heart rate, decreased myocardial contractility, and lower renin release after beta1-receptor inhibition. These effects provide a mechanistic basis for applications in hypertension, angina, arrhythmias, and selected heart failure cases. They also help distinguish the intended cardiovascular actions from possible beta2-related bronchial or vascular consequences when selectivity becomes less pronounced.